Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 January 2008

In vitro investigation of MRP 2 in the cyclosporine A – pravastatin interplay

R.l Kato, M. Nishide, C. Kodzu, Y. Ijiri, K. Tanaka

Ann Transplant 2008; 13(1): 34-34 :: ID: 880190

Abstract

Background: Cyclosporine A (CsA) has been used to treat a variety of autoimmune diseases. It is reported that CsA is metabolized by CYP3A and excreted via P-glycoprotein and multidrug resistant protein (MRP) 2 in humans. Pravastatin has been used to treat hyperlipidemia, and it is reported that pravastatin is excreted via MRP2 in humans. We had two cases where the blood CsA level was increased following pravastatin administration. It is suggested that CsA interacted with pravastatin via MRP2. In this study, we investigated the effects of pravastatin on CsA transport via MRP2.
Material/Methods: Caco 2 cells were seeded on Transwell® at a density of 105 cells/well. Calcein, a substrate of MRP, was put into Caco 2 cells, and CsA (5, 50 μM) and pravastatin (0.1, 1.0 mM) were added to the apical and basolateral sides (n = 6). After a 30 min incubation, calcein was effl uxed from Caco 2 cells, and the calcein level of the culture medium was assayed. CsA was put into Caco 2 cells, and pravastatin (0.1, 1.0 mM) was added to the apical and basolateral sides (n=3). After 1 hour of incubation, CsA was effluxed from Caco 2 cells and the CsA level of the culture medium was assayed.
Results: The calcein effl ux to the apical side was decreased significantly by the addition of pravastatin (1.0 mM) and CsA (5, 50 μM), respectively. The CsA efflux to the apical side was decreased significantly by the addition of pravastatin (1.0 mM).
Conclusions: The results demonstrate that CsA transport may
be inhibited competitively by pravastatin via MRP2.

Keywords: Cyclosporine, hyperlipidemia, Medullary Thyroid Cancer

Add Comment 0 Comments

In Press

07 Mar 2024 : Original article  

Outcomes of Renal Transplantation in ANCA-Associated Vasculitis

Ann Transplant In Press; DOI: 10.12659/AOT.943433  

08 Mar 2024 : Original article  

Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...

Ann Transplant In Press; DOI: 10.12659/AOT.943532  

14 Mar 2024 : Original article  

Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study

Ann Transplant In Press; DOI: 10.12659/AOT.943652  

14 Mar 2024 : Case report  

Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...

Ann Transplant In Press; DOI: 10.12659/AOT.942358  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358